CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling

Neoplasia (United States)

Volumn 16, Issue 3, 2014, Pages 265-278.e13

  Ma, Ming Ze ^a   Zhuang, Chun ^a   Yang, Xiao Mei ^a   Zhang, Zi Zhen ^a   Ma, Hong ^a   Zhang, Wen Ming ^b   You, Haiyan ^a   Qin, Wenxin ^a   Gu, Jianren ^a   Yang, Shengli ^a   Cao, Hui ^a   Zhang, Zhi Gang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1; IMATINIB; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CTHRC1 PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RAC1 PROTEIN; RAC1 PROTEIN, HUMAN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, HUMAN; SCLEROPROTEIN; WNT PROTEIN; WNT5A PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; TISSUE MICROARRAY; WESTERN BLOTTING; WNT SIGNALING PATHWAY; CELL MOTION; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS;

BENZAMIDES; CELL MOVEMENT; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; RAC1 GTP-BINDING PROTEIN; RHOA GTP-BINDING PROTEIN; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84900449416     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.03.001     Document Type: Article

References (50)

1. Joensuu H, Hohenberger P, and Corless CL (2013). Gastrointestinal stromal tumour. Lancet 382, 973-983.
2. Yang H, Shen C, Zhang B, Chen H, Chen Z, and Chen J (2013). Expression and clinicopathological significance of CD9 in gastrointestinal stromal tumor. J Korean Med Sci 28, 1443-1448.
3. Terada T (2013). Smooth muscles and stem cells of embryonic guts express KIT, PDGFRRA, CD34 and many other stem cell antigens: suggestion that GIST arise from smooth muscles and gut stem cells. Int J Clin Exp Pathol 6, 1038-1045.
4. Simon S, Grabellus F, Ferrera L, Galietta L, Schwindenhammer B, Muhlenberg T, Taeger G, Eilers G, Treckmann J, and Breitenbuecher F, et al (2013). DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors. Cancer Res 73, 3661-3670.
5. Hirano K, Shishido-Hara Y, Kitazawa A, Kojima K, Sumiishi A, Umino M, Kikuchi F, Sakamoto A, Fujioka Y, and Kamma H (2008). Expression of stem cell factor (SCF), a KIT ligand, in gastrointestinal stromal tumors (GISTs): a potential marker for tumor proliferation. Pathol Res Pract 204, 799-807.
6. Lv A, Li Z, Tian X, Guan X, Zhao M, Dong B, and Hao C (2013). SKP2 high expression, KIT exon 11 deletions, and gastrointestinal bleeding as predictors of poor prognosis in primary gastrointestinal stromal tumors. PLoS One 8, e62951.
7. Kubota D, Yoshida A, Tsuda H, Suehara Y, Okubo T, Saito T, Orita H, Sato K, Taguchi T, and Yao T, et al (2013). Gene expression network analysis of ETV1 reveals KCTD10 as a novel prognostic biomarker in gastrointestinal stromal tumor. PLoS One 8, e73896.
8. Shinomura Y, Kinoshita K, Tsutsui S, and Hirota S (2005). Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors. J Gastroenterol 40, 775-780.
9. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, Ramadori G, Hohenberger P, Duyster J, and Al-Batran SE, et al (2012). One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307, 1265-1272.
10. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, and Joensuu H, et al (2013). Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 295-302.
11. Miettinen M and Lasota J (2001). Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438, 1-12.
12. Mucciarini C, Rossi G, Bertolini F, Valli R, Cirilli C, Rashid I, Marcheselli L, Luppi G, and Federico M (2007). Incidence and clinicopathologic features of gastrointestinal stromal tumors A population-based study. BMC Cancer 7, 230.
13. Chen YL, Wang TH, Hsu HC, Yuan RH, and Jeng YM (2013). Overexpression of CTHRC1 in Hepatocellular Carcinoma Promotes Tumor Invasion and Predicts Poor Prognosis. PloS One 8, e70324.
14. Lu P, Weaver VM, and Werb Z (2012). The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196, 395-406.
15. Nguyen-Ngoc KV, Cheung KJ, Brenot A, Shamir ER, Gray RS, Hines WC, Yaswen P, Werb Z, and Ewald AJ (2012). ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium. Proc Natl Acad Sci U S A 109, E2595-604.
16. Pyagay P, Heroult M, Wang Q, Lehnert W, Belden J, Liaw L, Friesel RE, and Lindner V (2005). Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 96, 261-268.
17. Yamamoto S, Nishimura O, Misaki K, Nishita M, Minami Y, Yonemura S, Tarui H, and Sasaki H (2008). Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell 15, 23-36.
18. Park EH, Kim S, Jo JY, Kim SJ, Hwang Y, Kim JM, Song SY, Lee DK, and Koh SS (2013). Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. Carcinogenesis 34, 694-702.
19. Wang P, Wang YC, Chen XY, Shen ZY, Cao H, Zhang YJ, Yu J, Zhu JD, Lu YY, and Fang JY (2012). CTHRC1 is upregulated by promoter demethylation and transforming growth factor-beta1 and may be associated with metastasis in human gastric cancer. Cancer Sci 103, 1327-1333.
20. Tan F, Liu F, Liu H, Hu Y, Liu D, and Li G (2013). CTHRC1 is associated with peritoneal carcinomatosis in colorectal cancer: a new predictor for prognosis. Med Oncol 30, 473.
21. Joensuu H (2008). Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39, 1411-1419.
22. Rutkowski P, Bylina E, Wozniak A, Nowecki ZI, Osuch C, Matlok M, Switaj T, Michej W, Wronski M, and Gluszek S, et al (2011). Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 37, 890-896.
23. Zhang ZG, Lambert C, Servotte S, Chometon G, Eckes B, Krieg T, Lapiere C, Nusgens B, and Aumailley M (2006). Effects of constitutively active GTPases on fibroblast behavior. Cell Mol Life Sci 63, 82-91.
24. Steigen SE and Eide TJ (2009). Gastrointestinal stromal tumors (GISTs): a review. APMIS 117, 73-86.
25. Pidhorecky I, Cheney RT, Kraybill WG, and Gibbs JF (2000). Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 7, 705-712.
26. Lee EJ, Kang G, Kang SW, Jang KT, Lee J, Park JO, Park CK, Sohn TS, Kim S, and Kim KM (2013). GSTT1 copy number gain and ZNF overexpression are predictors of poor response to imatinib in gastrointestinal stromal tumors. PLoS One 8, e77219.
27. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, and Rubin BP, et al (2002). Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33, 459-465.
28. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, and Rubin BP, et al (2002). Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 10, 81-89.
29. Miao CG, Yang YY, He X, Li XF, Huang C, Huang Y, Zhang L, Lv XW, Jin Y, and Li J (2013). Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling. Cell Signal 25, 2069-2078.
30. Rabelo Fde S, da Mota LM, Lima RA, Lima FA, Barra GB, de Carvalho JF, and Amato AA (2010). The Wnt signaling pathway and rheumatoid arthritis. Autoimmun Rev 9, 207-210.
31. Spano D and Zollo M (2012). Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastasis 29, 381-395.
32. Niehrs C (2012). The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 13, 767-779.
33. Zeller J, Turbiak AJ, Powelson IA, Lee S, Sun D, Showalter HD, and Fearon ER (2013). Investigation of 3-aryl-pyrimido [5,4-e] [1,2,4]triazine-5,7-diones as small molecule antagonists of beta-catenin/TCF transcription. Bioorg Med Chem Lett 23, 5814-5820.
34. Choi SS, Witek RP, Yang L, Omenetti A, Syn WK, Moylan CA, Jung Y, Karaca GF, Teaberry VS, and Pereira TA, et al (2010). Activation of Rac1 promotes hedgehog-mediated acquisition of the myofibroblastic phenotype in rat and human hepatic stellate cells. Hepatology 52, 278-290.
35. Huang X, McGann JC, Liu BY, Hannoush RN, Lill JR, Pham V, Newton K, Kakunda M, Liu J, and Yu C, et al (2013). Phosphorylation of Dishevelled by protein kinase RIPK4 regulates Wnt signaling. Science 339, 1441-1445.
36. Yuan Y, Niu CC, Deng G, Li ZQ, Pan J, Zhao C, Yang ZL, and Si WK (2011). The Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt signaling in K562 cells. Int J Mol Med 27, 63-69.
37. Wada H and Okamoto H (2009). Roles of noncanonical Wnt/PCP pathway genes in neuronal migration and neurulation in zebrafish. Zebrafish 6, 3-8.
38. Gao B (2012). Wnt regulation of planar cell polarity (PCP). Curr Top Dev Biol 101, 263-295.
39. Miyoshi H, Ajima R, Luo CT, Yamaguchi TP, and Stappenbeck TS (2012). Wnt5a potentiates TGF-beta signaling to promote colonic crypt regeneration after tissue injury. Science 338, 108-113.
40. Katoh M (2005). WNT/PCP signaling pathway and human cancer (review). Oncol Rep 14, 1583-1588.
41. Otey C, Goicoechea S, and Garcia-Mata R (2009). Roles of the small GTPases RhoA and Rac1 in cell behavior. F1000 Biol Rep 1, 4.
42. Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, Kikuchi Y, Takada I, Kato S, and Kani S, et al (2012). Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 18, 405-412.
43. Kamai T, Yamanishi T, Shirataki H, Takagi K, Asami H, Ito Y, and Yoshida K (2004). Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin Cancer Res 10, 4799-4805.
44. Deakin NO, Ballestrem C, and Turner CE (2012). Paxillin and Hic-5 interaction with vinculin is differentially regulated by Rac1 and RhoA. PLoS One 7, e37990.
45. Chauhan BK, Lou M, Zheng Y, and Lang RA (2011). Balanced Rac1 and RhoA activities regulate cell shape and drive invagination morphogenesis in epithelia. Proc Natl Acad Sci U S A 108, 18289-18294.
46. Hill CS, Wynne J, and Treisman R (1995). The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. Cell 81, 1159-1170.
47. El-Sibai M, Pertz O, Pang H, Yip SC, Lorenz M, Symons M, Condeelis JS, Hahn KM, and Backer JM (2008). RhoA/ROCK-mediated switching between Cdc42- and Rac1-dependent protrusion in MTLn3 carcinoma cells. Exp Cell Res 314, 1540-1552.
48. Nethe M and Hordijk PL (2010). The role of ubiquitylation and degradation in RhoGTPase signalling. J Cell Sci 123, 4011-4018.
49. Patel S, Takagi KI, Suzuki J, Imaizumi A, Kimura T, Mason RM, Kamimura T, and Zhang Z (2005). RhoGTPase activation is a key step in renal epithelial mesenchymal transdifferentiation. J Am Soc Nephrol 16, 1977-1984.
50. Bravo-Cordero JJ, Moshfegh Y, Condeelis J, and Hodgson L (2013). Live cell imaging of RhoGTPase biosensors in tumor cells. Methods Mol Biol 1046, 359-370.